Clinical trials: Asthma Patients
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Asthma
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
This observational study aims to collect data in clinical practice on the clinical profile of patients treated with Tezepelumab from Q1 2024 to Q1 2025 according to the approved and reimbursed indication in Italy
- Trial name
- FRONTEDGE (NCT06948396)
- Testing
- Tezepelumab
- Where
- 28 sites in Italy
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Asthma
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
A study evaluating efficacy and safety of repeated doses of PT027 compared to PT007 in patients with asthma and acute airway obstruction induced by repeated mannitol challenges
- Trial name
- NCT05555290
- Testing
- PT027, PT007
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Asthma
MK0476 Study in Adult Patients With Acute Asthma (0476-322)
This study evaluates the efficacy and safety of MK0476 intravenous administration in adult patients with acute asthma.
- Trial name
- NCT00229970
- Testing
- montelukast sodium
- Volunteers
- 225 people
- Sponsor
- Organon and Co
Severe Asthma
Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium
This study aims to assess health and quality of life outcomes in patients treated with benralizumab, within a Belgian Real-World setting.
- Trial name
- BE-REAL (NCT04221802)
- Where
- 10 sites in Belgium
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing…
- Trial name
- NCT06052267
- Testing
- TEV-56248, Albuterol sulfate
- Where
- 393 sites in United States, Argentina and 20 more
- Volunteers
- 2,772 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Asthma
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with…
- Trial name
- NCT02918019
- Testing
- MSTT1041A
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 517 people
- Sponsor
- Hoffmann-La Roche
Asthma
Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists
This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.
- Trial name
- TRICHECO (NCT07546981)
- Testing
- Experimental: Participant Group CHF 5993 pMDI HFA-152a, Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a
- Where
- 2 sites in China
- Volunteers
- 554 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study Of Asthma In Patients Of African Descent
This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests.
- Trial name
- NCT00102765
- Testing
- fluticasone propionate/salmeterol powder, fluticasone propionate powder
- Where
- 75 sites in United States
- Volunteers
- 479 people
- Sponsor
- GlaxoSmithKline
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)
The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.), fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 220 mcg b.i.d. and placebo b.i.d.
- Trial name
- NCT01397201
- Testing
- BI 54903, Fluticasone propionate
- Where
- 41 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Allergy
A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites
A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.
- Trial name
- NCT00660452
- Testing
- Staloral
- Where
- China
- Volunteers
- 484 people
- Sponsor
- Stallergenes Greer
Asthma
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire…
- Trial name
- FORTUNE (NCT03453112)
- Testing
- Foster 100/6µg NEXThaler, Foster 100/6µg pMDI
- Where
- 51 sites in China
- Volunteers
- 494 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)
This study is designed to show that pharmacotherapy guided by eNO and clinical standard of care produces a superior outcome to trial-based therapy guided by clinical standard of care alone.
- Trial name
- Outcomes (NCT00739219)
- Testing
- Apieron Insight eNO monitor
- Where
- 12 sites in United States
- Volunteers
- 260 people
- Sponsor
- Apieron
Asthma
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.
- Trial name
- QAB149 (NCT01959412)
- Testing
- Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg
- Where
- 12 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study in Patients With Asthma
The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control group.
- Trial name
- NCT00215371
- Testing
- Formoterol Fumarate
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dey
Asthma
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose…
- Trial name
- NCT01396278
- Testing
- Fluticasone propionate, BI 54903
- Where
- 37 sites in United States
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Asthma
Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)
The aim of the study is to investigate the effect of ciclesonide versus fluticasone propionate versus placebo on airway hyperresponsiveness and on the hypothalamic-pituitary-adrenal axis (HPA axis).
- Trial name
- NCT00163332
- Testing
- Ciclesonide
- Where
- 5 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Asthma
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients with Asthma
- Trial name
- eMOFEE (NCT04869384)
- Testing
- Reminders and feedback to improve adherence, No reminders and feedback to improve adherence
- Where
- Germany
- Volunteers
- 158 people
- Sponsor
- Orion Corporation, Orion Pharma
Dyspnea
Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED
For the patient with acute dyspnea in the ED, early differentiation between CHF and non-CHF causes is essential for proper management.
- Trial name
- NCT01206621
- Where
- 8 sites in United States, Israel
- Volunteers
- 530 people
- Sponsor
- Deep Breeze
Asthma,, Chronic Obstructive Pulmonary Disease
Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct
The correct use of inhalation devices is an inclusion criterion for all studies comparing inhaled treatments. In real life, however, patients may make many errors with their usual inhalation device, which may negate the benefits…
- Trial name
- NCT01426893
- Where
- 5 sites in Serbia
- Volunteers
- 310 people
- Sponsor
- AstraZeneca